Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Co-Diagnostics, Inc. before investing.

In this article, we go over a few key elements for understanding Co-Diagnostics, Inc.’s stock price such as:

• Co-Diagnostics, Inc.’s current stock price and volume
• Why Co-Diagnostics, Inc.’s stock price changed recently
• Upgrades and downgrades for CODX from analysts
• CODX’s stock price momentum as measured by its relative strength

About Co-Diagnostics, Inc. (CODX)

Before we jump into Co-Diagnostics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Want to learn more about Co-Diagnostics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Co-Diagnostics, Inc..

Co-Diagnostics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 11:56 AM, CST, Co-Diagnostics, Inc.’s stock price was $1.450.

Co-Diagnostics, Inc. is down 7.05% from its previous closing price of $1.560.

During the last market session, Co-Diagnostics, Inc.’s stock traded between $1.420 and $1.640. Currently, there are approximately 2.25 million shares outstanding for Co-Diagnostics, Inc..

Co-Diagnostics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Co-Diagnostics, Inc. Stock Price History

Co-Diagnostics, Inc.’s (CODX) price is currently down 53.23% so far this month.

During the month of July, Co-Diagnostics, Inc.’s stock price has reached a high of $4.600 and a low of $1.380.

Over the last year, Co-Diagnostics, Inc. has hit prices as high as $46.500 and as low as $1.260. Year to date, Co-Diagnostics, Inc.’s stock is down 71.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Co-Diagnostics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Co-Diagnostics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Co-Diagnostics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Co-Diagnostics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Co-Diagnostics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Co-Diagnostics, Inc. (CODX) by visiting AAII Stock Evaluator.

Relative Price Strength of Co-Diagnostics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Co-Diagnostics, Inc. has a weighted four-quarter relative price strength of -5.82%, which translates to a Momentum Score of 32 and is considered to be Weak.

Want to learn more about how Co-Diagnostics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Co-Diagnostics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Co-Diagnostics, Inc.’s stock price is $1.450, which is down 7.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Co-Diagnostics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.